Compare SOPA & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOPA | CDIO |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | Singapore | United States |
| Employees | N/A | 17 |
| Industry | EDP Services | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2M | 4.6M |
| IPO Year | 2021 | N/A |
| Metric | SOPA | CDIO |
|---|---|---|
| Price | $0.08 | $1.96 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $22.50 | N/A |
| AVG Volume (30 Days) | ★ 2.3M | 67.6K |
| Earning Date | 05-19-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,171,635.00 | N/A |
| Revenue This Year | $2.43 | $171,906.75 |
| Revenue Next Year | $71.20 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 45.00 | N/A |
| 52 Week Low | $0.07 | $0.97 |
| 52 Week High | $6.28 | $7.91 |
| Indicator | SOPA | CDIO |
|---|---|---|
| Relative Strength Index (RSI) | 19.75 | 52.58 |
| Support Level | N/A | $1.68 |
| Resistance Level | $0.66 | $2.18 |
| Average True Range (ATR) | 0.04 | 0.22 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 2.06 | 53.78 |
Society Pass Inc is building an ecosystem of platforms and technology-enabled companies that synergistically work together to transform how consumers and merchants interact with one another in Southeast Asia and South Asia. Through the acquisition of companies and partnerships with entrepreneurs, the company meets the growing demand for services in sectors such as lifestyle, beauty, travel, and food and beverage. The company currently operates in Six reportable operating segments: Online Grocery and Food deliveries, Digital marketing, Online ticketing and reservation, Telecommunications Reseller, e-commerce, and Corporate. The company generates the majority of its revenue from the Digital marketing segment.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.